stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) EPS (diluted)
Penumbra, Inc.'s EPS (diluted) for fiscal 2025 was $4.52, up 1,155.6% from $0.36 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.97. Over the past ten years it has ranged from −$0.44 (fiscal 2020) to $4.52 (fiscal 2025) — the current reading is the highest in ten years. Penumbra, Inc. ranks 10th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $4.52 | 1,155.56% |
| FY2024 | $0.36 | (84.48%) |
| FY2023 | $2.32 | — |
| FY2022 | −$0.05 | — |
| FY2021 | $0.14 | — |
| FY2020 | −$0.44 | — |
| FY2019 | $1.34 | 644.44% |
| FY2018 | $0.18 | 38.46% |
| FY2017 | $0.13 | (70.45%) |
| FY2016 | $0.44 | 450.00% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.07 | 21.26% |
| Jun 2026 | $0.88 | 7.32% |
| Mar 2026 | $0.82 | (31.67%) |
| Dec 2025 | $1.20 | 2.56% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. | $3.97 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| TXG 10x Genomics compare | −$0.59 |
| BRKR Bruker Corporation compare | −$1.01 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PEN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement